Ken Griffin Beyond Spring Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Beyond Spring Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 200 shares of BYSI stock, worth $350. This represents 0.0% of its overall portfolio holdings.

Number of Shares

200

Holding current value

$350

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.44 - $1.8 $26,897 - $33,622	18,679 New	18,679 $26,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.39 $3,772 - $5,892	-4,239 Reduced 44.76%	5,232 $6,000
Q1 2023 May 15, 2023	BUY	$1.06 - $3.05 $3,143 - $9,046	2,966 Added 45.6%	9,471 $10,000
Q4 2022 Feb 14, 2023	SELL	$0.56 - $2.61 $53,205 - $247,976	-95,010 Reduced 93.59%	6,505 $12,000
Q3 2022 Nov 14, 2022	SELL	$0.97 - $1.81 $241,896 - $451,374	-249,378 Reduced 71.07%	101,515 $100,000
Q2 2022 Aug 15, 2022	BUY	$1.13 - $2.66 $82,546 - $194,313	73,050 Added 26.29%	350,893 $506,000
Q1 2022 May 16, 2022	SELL	$1.68 - $5.01 $341,646 - $1.02 Million	-203,361 Reduced 42.26%	277,843 $611,000
Q4 2021 Feb 14, 2022	BUY	$4.02 - $16.84 $843,444 - $3.53 Million	209,812 Added 77.31%	481,204 $2.18 Million
Q3 2021 Nov 15, 2021	BUY	$9.26 - $31.31 $1.56 Million - $5.29 Million	168,880 Added 164.74%	271,392 $4.28 Million
Q2 2021 Aug 16, 2021	BUY	$9.37 - $12.12 $587,386 - $759,778	62,688 Added 157.41%	102,512 $1.07 Million
Q1 2021 May 17, 2021	BUY	$10.61 - $15.77 $422,532 - $628,024	39,824 New	39,824 $441,000
Q3 2020 Nov 16, 2020	SELL	$9.99 - $16.13 $343,076 - $553,936	-34,342 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$11.21 - $18.15 $384,973 - $623,307	34,342 New	34,342 $518,000

Others Institutions Holding BYSI

# of Institutions

Shares Held

5.28M

Call Options Held

200

Put Options Held

View Full List

About BeyondSpring Inc.

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $68.1M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

More about BYSI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account